Hospira Mitoxantrone (concentrate) 30 mg/15 mL injection vial USP

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

mitoxantrone (mitozantrone) hydrochloride, Quantity: 2.33 mg/mL

Commercializzato da:

Hospira Australia Pty Ltd

INN (Nome Internazionale):

mitoxantrone (mitozantrone) hydrochloride

Forma farmaceutica:

Injection

Composizione:

Excipient Ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride; sodium metabisulfite

Via di somministrazione:

Intravenous Infusion

Confezione:

1 x 15 mL vial

Classe:

Medicine Listed (Export Only)

Tipo di ricetta:

Not scheduled. Not considered by committee

Indicazioni terapeutiche:

Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Dettagli prodotto:

Visual Identification: A clear, dark blue solution; Container Type: Vial; Container Life Time: 1 Years; Container Temperature: Store between 15-25 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2007-07-27